EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Obinutuzumab in Crescentic Anti-Glomerular Basement Membrane Disease with Linear IgG Deposition: A Case Report

Cheng Xue, Bo Yang, Xin Hong, Yuheng Lu, Yixin Qian, Xinming Li, Nanmei Liu, Jun Wu

Case Reports in Nephrology and Dialysis · 23.04.2026 · 16 (1) · 75-82

DOI: 10.1159/000552035 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Nephrology and Dialysis, online erschienen am 23.04.2026. Verfasst von Cheng Xue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shanghai Changzheng Hospital, Second Affiliated Hospital of Naval Medical University, Shanghai, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anti-glomerular basement membrane (anti-GBM) disease is a rare autoimmune vasculitis that often leads to rapidly progressive glomerulonephritis and poor renal prognosis. Standard treatment typically involves plasmapheresis, corticosteroids, and cyclophosphamide. However, the therapeutic role of obinutuzumab, a B-cell-depleting monoclonal antibody, remains under-explored in anti-GBM disease. Case Presentation: We report a 20-year-old male with isolated renal anti-GBM disease following a dental infection, who presented with severe acute kidney injury (creatinine >700 μmol/L), high anti-GBM antibody titers, and crescentic glomerulonephritis on biopsy. Despite initial therapy with plasmapheresis, corticosteroids, and cyclophosphamide, renal function deteriorated. Obinutuzumab (500 mg IV) was administered as adjunct therapy, leading to rapid antibody clearance within 1 month. Remarkably, the patient achieved partial renal recovery and was dialysis-independent by 3 months, with stable stage 3 chronic kidney disease at 5-month follow-up.

Conclusion

This case underscores the potential role of obinutuzumab as an innovative adjunctive therapy in severe anti-GBM disease, even in patients with traditionally poor prognostic markers. Early and aggressive multimodal treatment, including B-cell targeting, may improve outcomes in selected cases.

Schlagwörter

Stichwörter der Autor:innen

Anti-glomerular basement membrane diseaseGoodpasture’s syndromeObinutuzumab

Autor:innen und Institutionen

  • Department of Nephrology, Shanghai Changzheng Hospital, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Department of Nephrology, Naval Medical Center, Naval Medical University, Shanghai, China.
  • Department of Urology, Peking University International Hospital, Beijing, China.
  • Department of Nephrology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Zitieren

APA

Xue, C., Yang, B., Hong, X., Lu, Y., Qian, Y., Li, X., Liu, N., & Wu, J. (2026). Obinutuzumab in Crescentic Anti-Glomerular Basement Membrane Disease with Linear IgG Deposition: A Case Report. Case Reports in Nephrology and Dialysis, 16(1), 75-82. https://doi.org/10.1159/000552035

Vancouver

Xue C, Yang B, Hong X, Lu Y, Qian Y, Li X, et al. Obinutuzumab in Crescentic Anti-Glomerular Basement Membrane Disease with Linear IgG Deposition: A Case Report. Case Reports in Nephrology and Dialysis. 2026;16(1):75-82. doi:10.1159/000552035

BibTeX
@article{Xue2026,
  author = {Xue, Cheng and Yang, Bo and Hong, Xin and Lu, Yuheng and Qian, Yixin and Li, Xinming and Liu, Nanmei and Wu, Jun},
  title = {Obinutuzumab in Crescentic Anti-Glomerular Basement Membrane Disease with Linear IgG Deposition: A Case Report},
  journal = {Case Reports in Nephrology and Dialysis},
  year = {2026},
  volume = {16},
  number = {1},
  pages = {75--82},
  doi = {10.1159/000552035}
}
Kostenlos starten →